Molecular Mechanism of Inhibition of the Mitochondrial Carnitine/Acylcarnitine Transporter by Omeprazole Revealed by Proteoliposome Assay, Mutagenesis and Bioinformatics

Annamaria Tonazzi1, Ivano Eberini2, Cesare Indiveri1,3*

1 CNR Institute of Biomembranes and Bioenergetics, Bari, Italy, 2Laboratorio di Biochimica e Biofisica Computazionale, Dipartimento di Scienze Farmacologiche e Biomolecolari, Sezione di Biochimica, Biofisica, Fisiologia ed Immunopatologia, Università degli Studi di Milano, Milano, Italy, 3Department BEST (Biologia, Ecologia, Scienze della Terra), Unit of Biochemistry and Molecular Biotechnology, University of Calabria, Arcavacata di Rende, Italy

Abstract

The effect of omeprazole on the mitochondrial carnitine/acylcarnitine transporter has been studied in proteoliposomes. Externally added omeprazole inhibited the carnitine/carnitine antiport catalysed by the transporter. The inhibition was partially reversed by DTE indicating that it was caused by the covalent reaction of omeprazole with Cys residue(s). Inhibition of the C-less mutant transporter indicated also the occurrence of an alternative non-covalent mechanism. The IC50 of the inhibition of the WT and the C-less CACT by omeprazole were 5.4 μM and 29 μM, respectively. Inhibition kinetics showed non competitive inhibition of the WT and competitive inhibition of the C-less. The presence of carnitine or acylcarnitines during the incubation of the proteoliposomes with omeprazole increased the inhibition. Using site-directed Cys mutants it was demonstrated that C283 and C136 were essential for covalent inhibition. Molecular docking of omeprazole with CACT indicated the formation of both covalent interactions with C136 and C283 and non-covalent interactions in agreement with the experimental data.

Citation: Tonazzi A, Eberini I, Indiveri C (2013) Molecular Mechanism of Inhibition of the Mitochondrial Carnitine/Acylcarnitine Transporter by Omeprazole Revealed by Proteoliposome Assay, Mutagenesis and Bioinformatics. PLoS ONE 8(12): e82286. doi:10.1371/journal.pone.0082286

Editor: Gabriele Vincenzo Gnoni, University of Salento, Italy

Received September 18, 2013; Accepted October 30, 2013; Published December 9, 2013

Copyright: © 2013 Tonazzi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a grant from PON-ricerca e competitivita’ 2007–2013 - MIUR (PON project 01_00937: “Modelli sperimentali biotecnologici integrati per la produzione ed il monitoraggio di biomolecole di interesse per la salute dell’uomo.”) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The co-author Ivano Eberini is a PLOS ONE Editorial Board member. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: indiveri@unical.it

Introduction

Mitochondria represent important targets of pharmacological compounds. Indeed, exogenous substances interacting with mitochondrial enzymes or transporters may influence the entire cell metabolism. Among many proteins which have been shown to interact with pharmacological compounds [1], the carnitine/acylcarnitine transporter (CACT) emerged as a target of drugs [2,3]. The CACT has an essential role in the β-oxidation of fatty acids [4]. From studies performed in intact mitochondria and in proteoliposomes reconstituted with the purified or the recombinant protein, the function of the transporter has been well assessed. Physiologically, the transporter allows the entry of acyl groups, as acylcarnitines, into the mitochondrial matrix, for the β-oxidation. The free carnitine which is released in the matrix from acylcarnitines is transported back to the cytosol by the same transporter which catalyses an antiport reaction [4,5]. Inherited defects of the CACT gene cause a syndrome which is known as secondary carnitine deficiency [6] and is more severe than the primary carnitine deficiency caused by defects of the plasma membrane transporter OCTN2 [7]. The structure/function relationships of the transporter have been well characterized and several properties have been clarified using combined experimen-
secretion acting on the K⁺/H⁺-ATPase [14–18]. The pharmacological agent is activated at acidic pH in the gastric lumen and, after chemical modifications, it becomes reactive towards an SH group of the K⁺/H⁺-ATPase forming a mixed disulphide, which is responsible of the inhibition of the proton pump. A similar mechanism of interaction of omeprazole was also described for the plasma membrane carnitine (OCTN2) transport system of rat kidney. The drug causes inactivation of the transporter, by forming mixed disulphides with Cys residues of the protein [19]. By analogy, the mitochondrial carnitine/acylcarnitine transporter (CACT) may be a further potential target of omeprazole. Interestingly it has been found that omeprazole strongly inhibits the transport system. The structure/function relationships and the mechanism of the interaction of omeprazole with the CACT have been characterized by site-directed mutagenesis combined with molecular docking.

Materials and Methods

Materials

Sephadexes G-50, G-75 and G-200 were purchased from Pharmacia, t-[methyl-³H]carnitine 99% pure, 85 Ci/mmol, from Scoprus Research BV, Wageningen The Netherlands, egg-yolk phospholipids (1-γ-phosphatidylcholine from fresh turkey egg yolk), 1,4-piperazineethanesulfonic acid (Pipes), Triton X-100, cardiolipin, t-carnitine and N-dodecanoylsarcosine (sarkosyl) from Sigma-Aldrich. All other reagents were of analytical grade.

Site-directed mutagenesis, overexpression and isolation of the CACT proteins

The previously constructed pMW7-WTratCACT recombinant plasmid containing the wild-type (WT) CACT cDNA was used to introduce the mutations in the CACT protein [12]. The amino acid replacements were performed with complementary mutagenic primers using the overlap extension method and the High Fidelity PCR System [Roche]. The PCR products were purified and digested with NdeI and HindIII (restriction sites added at the 5′ end of forward and reverse primers, respectively) and ligated into the pMW7 expression vector. All mutations were verified by DNA sequencing, and, except for the desired base changes, all the sequences were identical to that of rat CACT cDNA. The resulting plasmids were transformed into E. coli C0214. Bacterial overexpression, isolation of the inclusion body fraction, solubilization and purification of the wild-type CACT and mutant CACT proteins were performed as described previously [12,20].

Reconstitution of wild-type and mutant CACT proteins in liposomes

The recombinant proteins were reconstituted into liposomes as described previously [12,20]. Briefly, a mixture was prepared with 60 µg protein, 1% Triton X-100, 10 mg phospholipids in the form of sonicated liposomes, 10 mM Pipes pH 7.0 and 15 mM carnitine in a final volume of 700 µl. The mixture was passed 15 times through the same Amberlite column (0.5 cm diameter x 3.2 cm height). The external substrate was then removed from proteoliposomes on Sephadex G-75 columns before the transport assay.

Transport measurements

Transport at 25 °C was started by adding 0.1 mM [³H]carnitine to proteoliposomes and terminated by the addition of 1.5 mM NEM. In controls, the inhibitor was added together with the labeled substrate, according to the inhibitor stop method [21,22]. This strategy allows subtracting, from the experimental samples, the aliquot of radio-labelled carnitine diffusing through the liposomal membrane. Finally, the external substrate was removed by chromatography on Sephadex G-50 columns, and the radioactivity in the liposomes was measured. The experimental values were corrected by subtracting control values. For efflux measurements, the proteoliposomes were loaded with radioactivity before starting the transport assay. This was achieved by incubating the proteoliposomes (600 µl), passed through Sephadex G-75 as described in Materials and methods, with 5 µM [³H]carnitine with a specific radioactivity of 10 nCi/nmol, for 60 min at 25 °C. Then, the external radioactivity was removed by passing again the proteoliposomes through Sephadex G-75 as described above except that this chromatography was performed at 4°C to minimize the loss of internal substrate during the chromatography. Transport (efflux) was started by adding external buffer or substrate and stopped at the appropriate time interval. The transport assay temperature was 25°C. Finally, each sample of proteoliposomes (100 µl) was passed through a Sephadex G-50 column to separate the external from the internal radioactivity. Efflux activity was expressed as intraliposomal cpm. Activation of omeprazole was obtained as follows: 25 mM omeprazole in ethanol was diluted 10 fold in HCl 0.1 M and incubated for 15 min. Then, the pH was adjusted to pH 6.0 by Tris powder.

Molecular modeling, docking, and low-mode molecular dynamics

CACT molecular model was built through the Swiss Model server (http://swissmodel.expasy.org) after an alignment with the bovine ADP/ATP carrier sequence. The alignment was inspected and manually adjusted with the Deep View software [23], and the output was used to run a SwissModel procedure in ‘Project Mode’.

Molecular docking was carried out with the Molecular Operating Environment (MOE) 2011.10. A database of the activated forms for protonic pump inhibitors (omeprazole, pantoprazole and lansoprazole) was built through the Builder module of MOE 2011.10. The structures were energy minimized with the MMFF94x force field. The final structures were saved in a database (mdb) file and then used for the molecular docking simulations.

The CACT binding site was identified through the MOE Site Finder module. This method is purely geometric and based not on energy models but on alpha spheres, which are a generalization of convex hulls [24]. Dummy atoms were positioned inside the binding site in order to carry out a more focused molecular docking procedure.

Docking was carried out with the MOE Dock program in its standard ‘Rigid Receptor’ mode (with all the parameters set as default). For each of the inhibitors bound to CACT, the top scoring solutions, as ranked according to the GBVI/WSA dG function, were selected. In order to optimize the interactions between ligands and receptor and to compute the affinity through the London dG empirical scoring function they were then submitted to a further refinement through the MOE LigX module. The dissociation constants for the complexes, expressed as pKi (-Log Ki), were computed from the affinity data.

Low mode molecular dynamics (LowModeMD) was used to generate putative conformations of CACT C89, C136, and C238 covalently bound to activated omeprazole. LowModeMD is aimed at focusing a MD trajectory along the low-mode vibrations and features a very efficient way versus classical MD for searching for minima troughs on the potential energy surface. To run these computations, we used the MOE Conformational Search program. This program uses an efficient implicit method for...
estimating the low-frequency modes and is based on the attenuation of high-range velocities, as described in detail in [25]. A molecule of activated omeprazole was bound to C89 or C136 or C238 in CACT with the MOE Builder. The omeprazole atoms were left free to move during the LowModeMD, whereas the residues more than 4.5 Å apart were fixed (not free to move, but used for the energy calculations); the other residues were defined as inert (fixed and not used for energy calculations). The simulation was carried out with default parameters. Two hundred and fifty structures were generated and ranked according to the value of the potential energy of the conformation. The conformations with strain energy lower than 2 kcal/mol versus the lowest energy conformation were analyzed. One among the conformations in which Cys238 was covalently bound to activated omeprazole (conformation #5) was used to dock omeprazole, according to the already described procedure.

Other methods
SDS-PAGE was performed as previously described [12]. The amount of recombinant protein was estimated on Coomassie-blue stained SDS-PAGE gels by using the Chemidoc imaging system equipped with Quantity One software (Bio-Rad) as previously described [26].

Results
Inhibition of the carnitine transporter by omeprazole
The effect of omeprazole on the carnitine transporter reconstituted in liposomes was investigated. The transport activity was measured as [100 μM (1H)Carnitine uptake into proteoliposomes containing 15 mM Carnitine, (Carnitine/Carnitine homologous antiport) in the presence of externally added 30 μM omeprazole activated by pre-incubation at pH 1.0 (see Materials and methods and refs. [15–18]), or non activated, i.e. kept in a buffer at pH 7.0 before the use. The time course of the carnitine transport is shown in Fig. 1. The accumulation of labeled carnitine into the proteoliposomes depended on the time, it increased up to 4.2 mmol g protein⁻¹ at 60 min. 30 μM activated omeprazole strongly inhibited the transport. At 10 min about 80% inhibition was found. At 60 min the transport was still inhibited by about 85%; whereas the addition of the non-activated compound had no inhibitory effect. The experimental data were interpolated in a first order rate equation from which the initial rate of transport was calculated as the product of the first order rate constant, k and the transport at equilibrium. The initial transport rate in the presence or absence of omeprazole was 0.30 or 0.045 mmol min⁻¹ g protein⁻¹, respectively. The two forms of activated omeprazole have functional groups [17] that could react with Cys residues of the protein forming a mixed disulphide, as it was previously found in the case of the gastric H⁺/K⁺-ATPase [16,17] and of the plasma carnitine carrier [18].

Figure 1. Effect of omeprazole on the carnitine antiport mediated by CACT. Transport was measured as described in Materials and methods adding 0.1 mM [3H]Carnitine at time zero to proteoliposomes containing 15 mM Carnitine in the absence (○, △, ▲) or in the presence of activated (●, ■) or non-activated (□) 30 μM omeprazole. In (▲) 2 mM DTE was added 2 min before the transport start. In (△) 2 mM DTE was added 10 min after the start to the proteoliposomes treated with omeprazole. In (▼) the proteoliposomes were pre-incubated with omeprazole and passed through Sephadex G-75 column to remove the non reacted reagent before the transport assay. The transport reaction was stopped at the indicated times, as described in Materials and methods. Reported values are means ± S.D. from three experiments of mmol of transported substrate per g of protein (mmol · g protein⁻¹).

doi:10.1371/journal.pone.0082286.g001

Figure 2. Dose-response curves for the inhibition of the reconstituted WT and C-less CACT by omeprazole. The carnitine/carnitine antiport rate was measured as described in Materials and methods, adding 0.1 mM [3H]Carnitine together with the indicated concentrations of omeprazole to proteoliposomes reconstituted with WT (●) or C-less (□) CACT. % residual activities with respect to the control are reported. The values are means ± S.D. from three experiments.

doi:10.1371/journal.pone.0082286.g002
Figure 3. Kinetic analysis of the inhibition of the reconstituted CACT by omeprazole. The carnitine/carnitine antiport rate was measured, as described in Materials and methods, adding [3H]carnitine at different concentrations to proteoliposomes reconstituted with WT CACT (A–C) or C-less CACT (B) containing 15 mM carnitine, in the absence (○) or in the presence of external omeprazole to proteoliposomes. In A, B and C the respective omeprazole concentrations were: 5–20 μM (●) and 10–40–68 μM (□). In C, 2 mM DTE was added together with omeprazole. Experimental data plotted according to Lineweaver-Burk as reciprocal transport rate vs reciprocal carnitine concentrations. Reported values are means ± S.D. from three experiments of reciprocal of μmol of transported substrate per mg of protein per min (min⁻¹ · mg⁻¹ · μmol⁻¹). doi:10.1371/journal.pone.0082286.g003

membrane OCTN2 transporter [19]. SH group(s) of Cys of the CACT are exposed towards the external side of the proteoliposomes, which corresponds to the cytoplasmic side of the transporter [9,27]. These Cys could be involved in the mechanism of inhibition by omeprazole via the formation of mixed disulphide(s). To evaluate this hypothesis the effect of dithioerythritol (DTE), a disulphide reducing agent, was tested. The addition of DTE to the proteoliposomes, after 10 min treatment with activated omeprazole, led to partial recovery of the transport function, which was clearly evident at 60 min of transport; about 78% of the activity was rescued respect to the inhibited sample. As a control, DTE was added to the untreated protein; no appreciable effects were observed. The incomplete recovery of the transport function caused by DTE may indicate that only a fraction of the transporter-omeprazole mixed disulphide linkage was reversed by DTE or that omeprazole was also able to inhibit the transporter by interactions different from the disulphide formation. To ascertain the presence of non-covalent interaction, the same experiment was performed on the C-less CACT, which has an intrinsic activity lower than the WT [27] but sufficient for evaluating the effect of the inhibitor. Indeed, omeprazole inhibited also the C-less protein, even though at a lower extent respect to the WT with a calculated initial rate of 0.051 mmol min⁻¹ g protein⁻¹, i.e. 40% of that of C-less CACT in the absence of omeprazole, 0.127 mmol min⁻¹ g protein⁻¹ (Fig. 1). No recovery of transport function was exerted by the addition of DTE in the case of the C-less CACT (not shown). This data indicated that the compound interacted with the protein also in the absence of Cys residues, i.e. non-covalently. To unequivocally demonstrate that the inhibition observed on the WT protein was actually due to the formation of mixed disulphide(s) between omeprazole and SH residues of the protein, a strategy, previously described for other transporters [3,19,28], was adopted. The proteoliposomes reconstituted with the wild type CACT were pre-incubated with omeprazole and then passed through Sephadex G-75 columns to remove the excess reagent. As shown in Fig. 1, the inhibition was maintained after the Sephadex G-75 chromatography, indicating that omeprazole was covalently bound (by mixed disulphide) to the transporter. Since the formation of mixed disulphides should be facilitated by alkaline pH, a similar experiment was performed at pH 8.0, even though at this pH the CACT has a lower activity. The extent of inhibition was nearly identical than that at pH 7.0 (not shown).

Kinetics of the inhibition of the carnitine transporter by omeprazole

To characterize the effect of omeprazole caused by the two different mechanisms of interaction with the transporter, kinetic experiments were performed on the WT or C-less protein. The dependence of the inhibition on the concentration of omeprazole was studied. The antiport rate, measured as uptake of 100 μM [3H]carnitine into proteoliposomes containing 15 mM carnitine, was determined in the presence of increasing concentration of the pharmacological agent. The dose response curves obtained are shown in Fig. 2. Nearly complete inhibition of the transport was observed with the WT at about 300 μM omeprazole; the calculated IC₅₀ from 3 experiments was 5.4±0.23 μM. In the case of C-less protein maximal inhibition was observed at 1.8 mM and the IC₅₀ was 29±8.5 μM. The same experiment was performed on the WT, adding omeprazole to the proteoliposomes in the presence of DTE. Under this condition i.e., the pharmacological agent could not covalently bind the transporter (see Materials and methods), the experimental data resembled those obtained with the C-less protein (not shown). The IC₅₀ of the WT CACT were also determined for pantoprazole (6.4±0.33 μM) and lansoprazole (80±23 μM) (experiments not shown). Inhibition kinetic studies were further performed on
Omeprazole to obtain data on the localization of the omeprazole binding respect to the substrate binding site. The dependence of the antiport rate on the external carnitine concentration was studied in the absence or presence of activated omeprazole. The data obtained on the WT and C-less CACT, analyzed in double reciprocal (Lineweaver-Burk) plot are shown in Fig. 3. In the case of WT (Fig. 3A) the experimental data were interpolated by three straight lines, which showed a common intersection point on the abscissa. This behavior is typical of non-competitive inhibition. The half saturation constant (Ki) for the inhibitor, derived from the plot, was 10.6 ± 1.6 μM (from three experiments). In the case of the C-less protein (Fig. 3B), the data were interpolated by three straight lines that, differently from the WT experiment, showed a common intersection close to the ordinate, typical of a competitive type of inhibition. The half saturation constant (Ki) for the inhibitor, derived from the plot, was 29.5 ± 1.2 μM, higher than that obtained for the WT. Results similar to those obtained with the C-less protein were observed on the WT in the presence of DTE, with a Ki of 42.5 ± 14.9 μM (Fig. 3C). In the case of covalent inhibition, as that determined by omeprazole on the WT, a non-competitive pattern could be obtained also if the inhibition site is in the substrate binding site. This can be discriminated studying the effect of protection of substrate on the inhibition as described in Fig. 4. The incubation of the proteoliposomes with 30 μM omeprazole in the absence of carnitine led to inhibition of 46 ± 7%. If 1 mM or 15 mM carnitine was added before the omeprazole, surprisingly, the inhibition increased to 80% and 92%, indicating that the omeprazole reaction with the transporter was not protected but facilitated by the presence of carnitine. A similar experiment was performed with other substrates of the CACT which have higher affinity respect to carnitine, octanoylcarnitine (0.05–0.5 mM) and palmitoylcarnitine (0.02–0.1 mM). Also the pre-incubation with these substrates increased the inhibition extent to 57% and 74% in the case of octanoylcarnitine or to 79% and 76% in the case of palmitoylcarnitine, respectively.

Identification of cysteine residues responsible for omeprazole covalent inhibition

To identify the Cys residue(s) that could react with omeprazole, the inhibition of Cys mutants of CACT lacking one or more Cys residues was analyzed. All the mutants lacking only one of the Cys residues were inhibited by more than 80% except the C136S, which was inhibited by 59% and the C283A, which showed an inhibition of 53% (Fig. 5). This indicated a major role of C136 and C283 in the interaction with omeprazole. The results were confirmed by the 54% inhibition of the mutant containing only...
omeprazole 0.15 mM, 5 mM DTE and carnitine 0.5 mM according to the legend added at time 0. The values are means ± S.D. from three experiments.

Molecular docking of omeprazole and also of pantoprazole and lansoprazole demonstrated that these ligands can form stable complexes with CACT through a set of non-covalent interactions. The docking score was used to select the top scoring poses among the 30 generated for each ligand. All the values were negative, suggesting that these ligands can bind to CACT central cavity. The computed dissociation constants $K_i$ for the top scoring complexes suggest the following rank of affinity towards CACT: omeprazole ≈ pantoprazole > lansoprazole (Tab. 1). For omeprazole, which has been extensively characterized in the reported experiments, we computed a $K_i$ of approx. 22 μM. In Figure 7B, a plot showing the CACT amino acids involved in omeprazole molecular recognition are highlighted. Several basic residues (K35, K135, R178, R219 and R275), two acidic residues (E132 and D231), a cysteine (C136), and both some polar and some apolar residues are clearly identified as interacting with omeprazole. Very interestingly most of these residues were previously found to be involved in the binding of substrate [30].

Three LowModeMD simulations were performed in order to evaluate the possibility that activated omeprazole could covalently bind to CACT cysteines, C89, C136 and C238. We analyzed 250 solutions for each simulation, and counted the number of solutions with strain energy lower than 2 kcal/mol versus the conformation with the lowest energy. We also evaluated the interaction potential energies between omeprazole and CACT of the lowest energy solutions for the three simulations (one for each of the studied cysteines). From our computations, C283 seems the most likely to covalently bind to omeprazole, since 9 conformations out of 250 showed a strain energy lower than 2 kcal/mol and the best solution had an energy of $-29.9$ kcal/mol. An intermediate reactivity can be hypothesized for C89, with 3 conformations under 2 kcal/mol and potential omeprazole-CACT interaction energy of $-23.6$ kcal/mol. The least reactive should be C136, with just 2 solutions under 2 kcal/mol and potential omeprazole-CACT interaction energy of $-19.3$ kcal/mol. From our $in silico$ results, all the investigated Cys could thus theoretically react with activated omeprazole, forming covalent mixed disulphide bonds. The proposed reactivity order is C283>C89>C136. C89 is, however, excluded by the experimental data on CACT mutants. On the basis of these observations, we selected one of the generated solutions for CACT covalently bound to omeprazole on C283, and we docked it with omeprazole. We obtained a set of 23 energetically favored (negative) solutions, with a top docking-score of $-6.64$ kcal/mol for the non-covalently bound omeprazole molecule. Through this procedure, we demonstrated the possibility that CACT could bind at the same time two omeprazole molecules; one covalently bound to C283 and another non-covalently bound inside the CACT central cavity. This solution is depicted in Fig. 7A.
Inhibition of Carnitine Carrier by Omeprazole

Discussion

In the present study, the proteoliposome system reconstituted with the recombinant mitochondrial CACT has been used for investigating the inhibition of the transporter by omeprazole. The compound forms S-S mixed disulphide(s) with critical Cys residues or week interactions with the substrate binding site, which are observed as irreversible or competitive inhibition, respectively. The WT transporter contains thiol groups of Cys exposed towards the extraliposomal environment, which corresponds to the cytosolic side of the transporter [9]. In this context the pharmacological agent after activation by acidic pH as it occurs physiologically in the gastric environment, could react covalently with these Cys residues [14–16,18,31]. C283 and C136 have been identified as targets of omeprazole, on the basis of data obtained with mutant proteins. The two Cys residues are exposed in the central cavity of the transporter, which face the extra-mitochondrial environment. C136 is in the bottom of the cavity just below the substrate binding site and was previously found to be the main target of small SH reagents such as NEM, which inactivate the transporters; while C283 is located in the upper part of the cavity, far from the carnitine binding site and is not involved in the inhibition by SH reagents [9,20]. Omeprazole which is much larger than NEM inhibits the transport upon binding to C283 causing steric hindrance and interferences with the translocation process. The relatively high affinity of the transporter for omeprazole (IC50 5.4 μM) should rely on the covalent bond formation and also on several week interactions of hydrophobic and aromatic groups of the compound with hydrophobic residues of the CACT which are located in the neighborhood of C283, as previously described [11]. The double mechanism of interaction is also confirmed by the computational analysis, which predicts the binding of omeprazole in the central cavity of the protein (Fig. 7A). At an upper, more external level, the covalent binding with C283 is predicted for an omeprazole molecule. At a lower level the binding of omeprazole in a non covalent mode is also predicted. This location, which overlaps the substrate binding site, is in agreement with the competitive interaction observed in the C-less protein. Indeed, the computational analysis revealed that the interaction of omeprazole with the transporter involves residues which were previously found to constitute the substrate binding site of carnitine [30]. The possible formation of a disulphide with C136, placed just below the substrate binding site, is experimentally demonstrated and fits very well with the positioning of omeprazole in the lower level. Both methodologies concur to indicate that omeprazole binds to C136 with lower efficiency respect to C283 (see Results section 3.5 and Fig. 4). Indeed, the slightly lower inhibition of the mutant lacking C283 than of the mutant lacking C136, indicates that this second covalent bond is somewhat less efficient than that with C283; this is confirmed by the finding that the mutant Cless-C136, containing the single C136 residue, and the mutant C283S show the same extent of inhibition (Fig. 4). Surprisingly, the covalent interactions of omeprazole with the Cys residues involved in the inhibition are facilitated by the presence of the substrate. This is explained by conformational changes occurring in this moiety of the protein upon substrate binding [11], which improves the accessibility of C283. This also explains why the pre-incubation with omeprazole produces a stronger inhibition compared to co-incubation during transport assay as observed in Fig. 1. Indeed in pre-incubation procedure the proteoliposomes have 15 mM external carnitine which is then removed by Sephadex G-75 chromatography before the transport assay (see Materials and methods). The similarity of some aspects of the inhibition of the mitochondrial transporter with those previously found for the plasma membrane OCTN2 transporter, which however were not described at the molecular level [19], indicates that the substrate binding sites should have some similar properties, in spite of the very different primary structures and affinity for substrates of the two proteins. [11,32]. These similarities explain also the common interactions among the two transporters and some drugs, such as β-lactam antibiotics.
Table 1. Docking scores (kcal/mol) and binding free energies (kcal/mol) for the top-scoring complexes between CACT and three protonic pump inhibitors.

| Ligand       | Docking score (kcal/mol) | Binding free energy (kcal/mol) | Calculated Ki (μM) | pKi  |
|--------------|--------------------------|-------------------------------|--------------------|------|
| Omeprazole   | −6.49                    | −6.31                         | 22                 | 4.64 |
| Pantoprazole | −6.46                    | −6.36                         | 21                 | 4.68 |
| Lansoprazole | −5.45                    | −5.41                         | 104                | 3.98 |

doi:10.1371/journal.pone.0082286.t001

previously described [3,33]. As it was reported for the OCTN2, the IC50 of CACT for omeprazole is below the plasma concentrations of the compound following the pharmacological administration. To predict the possible in vivo implications of the results described, it should be taken into account that the CACT transporter is essential in most tissues for the process of fatty acid β-oxidation. The defects of the CACT function, known as secondary carnitine deficiencies, are characterized by encephalopathy, respiratory distress, cardiomyopathy, muscle weakness, myopathy, vomiting and others [34]. The inhibition by omeprazole may lead to a mild deficiency-like syndrome. This correlates well with the symptoms like stomach pain, dizziness, difficult breathing, muscle spasm, tightening and cramping, which are described as side effects of omeprazole [see on the WEB: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id = 4761]. Moreover it has been demonstrated that omeprazole can enter the cells in the activated form leading to toxicity at gastric level due to oxidative damage caused by the interaction and oxidation of Cys residues of proteins [31,35,36]. The mechanism of interaction with the CACT could contribute to the oxidative damage as recently found in the case of H2O2 [27].

In the light of the data presented, the described experimental approach may have on the one hand utility for predicting side interaction of pump inhibitor analogues with the CACT and, hence, improve their safety. On the other hand such tools could be useful for searching specific inhibitors of the CACT, which are of interest, for example, as cardioprotective agents, as it was previously described for mildronate which plays benefits under ischemic conditions [2].

Author Contributions

Conceived and designed the experiments: CI AT IE. Performed the experiments: AT IE. Analyzed the data: AT CI IE. Contributed reagents/materials/analysis tools: CI. Wrote the paper: CI AT IE.

References

1. Szewczyk A, Wojtczak L (2002) Mitochondria as a pharmacological target. Pharmacol Rev 54: 101–127.
2. Oppedisano F, Fanello D, Calvani M, Indiveri C (2008) Interaction of mildronate with the mitochondrial carnitine/acylcarnitine transport protein. J Biochem Mol Toxicol 22: 8–14.
3. Pochini L, Galluccio M, Scumaci D, Giangregorio N, Tonazzi A, et al. (2008) Interaction of beta-lactam antibiotics with the mitochondrial carnitine/acylcarnitine transporter. Chemico-Biological Interactions 173: 167–194.
4. Pande SV (1975) A mitochondrial carnitine acylcarnitine translocase system. Proc Natl Acad Sci U S A 72: 883–887.
5. Indiveri C, Tonazzi A, Palmieri F (1996) Identification and purification of the carnitine carrier from rat liver mitochondria. Biochim Biophys Acta 1020: 81–96.
6. Stanley CA, Hale DE, Berry GT, Deleeuw S, Boxer J, et al. (1992) Brief report: a mitochondrial carnitine-acylcarnitine carrier. Eur J Biochem 208: 763–772.
7. Indiveri C, Pochini L, Oppedisano F, Tonazzi A (2010) The Carnitine Transporter Network: Interactions with Drugs. Current Chemical Biology 4: 108–123.
8. Giangregorio N, Tonazzi A, Indiveri C, Palmieri F (2007) Conformation-dependent accessibility of Cys-136 and Cys-155 of the mitochondrial rat carnitine/acylcarnitine carrier to membrane-impermeable SH reagents. Biochimica Et Biophysica Acta-Biogenic Nucleotides 1767: 1331–1339.
9. Tonazzi A, Giangregorio N, Indiveri C, Palmieri F (2005) Identification by site-directed mutagenesis and chemical modification of three vicinal cysteine residues in rat mitochondrial carnitine/acylcarnitine transporter. Journal of Biological Chemistry 280: 19607–19612.
10. Tonazzi A, Giangregorio N, Indiveri C, Palmieri F (2009) Site-directed mutagenesis of the His residues of the rat mitochondrial carnitine/acylcarnitine carrier: Implications for the role of His-29 in the transport pathway. Biochimica Et Biophysica Acta-Biogenic Nucleotides 1787: 1009–1015.
11. Tonazzi A, Console L, Giangregorio N, Indiveri C, Palmieri F (2012) Identification by site-directed mutagenesis of a hydrophobic binding site of the mitochondrial carnitine/acylcarnitine carrier involved in the interaction with acyl groups. Biochimica Et Biophysica Acta-Biogenic Nucleotides 1817: 697–704.
12. Indiveri C, Iacobazzi V, Giangregorio N, Palmieri F (1998) Bacterial overexpression, purification, and reconstitution of the carnitine/acylcarnitine carrier from rat liver mitochondria. Biochem Biophys Res Commun 249: 589–594.
13. Indiveri C, Tonazzi A, Giangregorio N, Palmieri F (1995) Probing the active site of the reconstituted carnitine carrier from rat liver mitochondria with sulphydryl reagents. A cysteine residue is localized in or near the substrate binding site. Eur J Biochem 220: 271–278.
14. Lorentzon P, Ekholm B, Brandstrom A, Wallmark B (1985) The mechanism for inhibition of gastric (H+ + K+)-ATPase by omeprazole. Biochim Biophys Acta 817: 23–32.
15. Lambrecht N, Corbett Z, Bayle D, Karlberg SJ, Sachs G (1998) Identification of the site of inhibition by omeprazole of a alpha-beta fusion protein of the H(K)-ATPase using site-directed mutagenesis. J Biol Chem 273: 13719–13720.
16. Beuson M, Simon A, Sachs G, Shin JM (1997) Sites of reaction of the gastric H(K)-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272: 22438–22446.
17. Shin JM, Cho YM, Sachs G (2004) Chemistry of covalent inhibition of the gastric (H+ + K+)-ATPase by proton pump inhibitors. J Am Chem Soc 126: 7800–7811.
18. Im WB, Sh J, Blakeman DP, McGrath JP (1985) Omeprazole, a specific inhibitor of gastric (H+ + K+)-ATPase, is a H+-activated oxidizing agent of sulphydryl groups. J Biol Chem 260: 4591–4597.
19. Pochini L, Scalise M, Indiveri C (2009) Inactivation by omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes. Chem Biol Interact 179: 394–401.
20. Indiveri C, Giangregorio N, Iacobazzi V, Palmieri F (2002) Site-directed mutagenesis and chemical modification of the six native cysteine residues of the rat mitochondrial carnitine carrier: implications for the role of cysteine-136. Biochemistry 41: 8649–8656.
21. Palmieri F, Indiveri C, Bisacca F, Iacobazzi V (1995) Mitochondrial metabolite carrier proteins: purification, reconstitution, and transport studies. Methods Enzymol 269: 349–369.
22. Indiveri C, Abruzzo G, Stipani I, Palmieri F (2000) Identification and purification of the reconstitutively active glutamine carrier from rat kidney mitochondria. Biochem J 353 (Pt 2): 285–290.
23. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
24. Elidesbrunner H FM, Fu R, Liang J (1995) Proceedings of the 21th Hawaii international conference on systems science.
25. Labute P (2010) LowModeMD—implicit low-mode velocity filtering applied to conformational search of macromolecules and protein loops. J Chem Inf Model 50: 792–800.
26. Galluccio M, Brizzo C, Torchetti EM, Ferranti P, Gianazza E, et al. (2007) Over-expression in Escherichia coli, purification and characterization of isoform 2 of human FAD synthetase. Protein Expr Purif 52: 175–181.
27. Tonazzi A, Console L, Indiveri C (2013) Inhibition of mitochondrial carnitine/acylcarnitine transporter by H_2O_2: Molecular mechanism and possible implication in pathophysiology. Chem Biol Interact.

28. Tonazzi A, Giangregorio N, Palmieri F, Indiveri C (2005) Relationships of Cysteine and Lysine residues with the substrate binding site of the mitochondrial ornithine/citrulline carrier: An inhibition kinetic approach combined with the analysis of the homology structural model. Biochimica Et Biophysica Acta-Biomembranes 1718: 53–60.

29. Indiveri C, Tonazzi A, Palmieri F (1991) Characterization of the unidirectional transport of carnitine catalyzed by the reconstituted carnitine carrier from rat liver mitochondria. Biochim Biophys Acta 1069: 110–116.

30. Giangregorio N, Tonazzi A, Console L, Indiveri C, Palmieri F (2010) Site-directed mutagenesis of charged amino acids of the human mitochondrial carnitine/acylcarnitine carrier: Insight into the molecular mechanism of transport. Biochimica Et Biophysica Acta-Bioenergetics 1797: 839–843.

31. Zomorodi K, Houston JB (1997) Selectivity of omeprazole inhibition towards rat liver cytochromes P450. Xenobiotica 27: 49–58.

32. Pochini L, Oppedisano F, Indiveri C (2004) Reconstitution into liposomes and functional characterization of the carnitine transporter from renal cell plasma membrane. Biochim Biophys Acta 1661: 78–86.

33. Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, et al. (2000) beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 275: 1699–1707.

34. Indiveri C, Jacobazzi V, Tonazzi A, Giangregorio N, Infanzino V, et al. (2011) The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology. Molecular Aspects of Medicine 32: 223–233.

35. Shin JM, Kim N (2013) Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 19: 25–35.

36. Inñarrea P, Casanova A, Alava MA, Iturralde M, Cadenas E (2011) Melatonin and steroid hormones activate intermembrane Cu,Zn-superoxide dismutase by means of mitochondrial cytochrome P450. Free Radic Biol Med 50: 1573–1581.